Alnylam Pharmace. buy Jefferies Financial Group Inc.
Start price
30.10.25
/
50%
€389.00
Target price
30.10.26
€472.69
Performance (%)
-33.65%
Price
28.04.26
€258.10
Summary
This prediction is currently active. Massive losses of -33.65% have been the result for the BUY prediction by Jefferies_Financial_. This prediction currently runs until 30.10.26. The prediction end date can be changed by Jefferies_Financial_ at any time. Jefferies_Financial_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -1.938% | -1.938% |
| iShares Core DAX® | -0,37 % | 8,40 % |
| iShares Nasdaq 100 | 2,27 % | 15,23 % |
| iShares Nikkei 225® | 1,43 % | 14,42 % |
| iShares S&P 500 | 1,22 % | 10,49 % |
Comments by Jefferies_Financial_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Jefferies Financial Group Inc. from $550.00 to $549.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Jefferies_Financial_ for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€273.90
07.07.25
07.07.25
€326.17
07.07.26
07.07.26
-5.77%
28.04.26
28.04.26
